
| COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial #MMPMID33245754Mancia GCardiovasc Res 2020[Dec]; 116 (14): e198-e199 PMID33245754show ga
?|Angiotensin Receptor Antagonists/adverse effects/*therapeutic use[MESH]|Angiotensin-Converting Enzyme 2/metabolism[MESH]|Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use[MESH]|COVID-19/mortality/physiopathology/therapy/*virology[MESH]|Host-Pathogen Interactions[MESH]|Humans[MESH]|Hypertension/*drug therapy/mortality/physiopathology[MESH]|Multicenter Studies as Topic[MESH]|Randomized Controlled Trials as Topic[MESH]|Renin-Angiotensin System/*drug effects[MESH]|Risk Assessment[MESH]|Risk Factors[MESH]|SARS-CoV-2/*drug effects/pathogenicity[MESH]|Treatment Outcome[MESH]
  
DeepDyve Pubget Overpricing | 
|